<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content





Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.

NEW! Champions' AACR 2024 Posters
Clinical Flow Cytometry
Hematological Malignancies
Humanized Models
Lumin Acuity
Solid Tumor PDX Models
TumorGraft3D & Co-Culture Platforms